Can Health Canada protect Canadians from unsafe drugs?

Hebert, Paul C.; Stanbrook, Matthew B.; MacDonald, Noni; Flegel, Ken; Coutts, Jane; MacLeod, Stuart
July 2011
CMAJ: Canadian Medical Association Journal;7/12/2011, Vol. 183 Issue 10, p1125
Academic Journal
The author reflects on the role of Health Canada in protecting Canadians from unsafe drugs. It states that under federal Food and Drugs Act, Canadians are inadequately protected from unsafe drugs which gives Health Canada with a task to ensure that both old and new medications are safe and effective. It cites the partnership of Health Canada and Canadian Institutes of Health Research (CIHR) to invest in a drug safety and effective safety measures.


Related Articles

  • Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Rostami-Hodjegan, Amin; Tucker, Geoffrey T. // Nature Reviews Drug Discovery;Feb2007, Vol. 6 Issue 2, p140 

    The perceived failure of new drug development has been blamed on deficiencies in in vivo studies of drug efficacy and safety. Prior simulation of the potential exposure of different individuals to a given dose might help to improve the design of such studies. This should also help researchers to...

  • Amgen best-seller challenged by generics. Ratner, Mark // Nature Biotechnology;Sep2013, Vol. 31 Issue 9, p774 

    The article presents research which suggests the effectiveness of combined inexpensive drugs to biologic Enbrel from Amgen for treating rheumatoid arthritis patients. The study points out that generic drugs can be as expensive as the branded biologics for this disease. It also notes that...

  • DEVELOPMENT OF DIETARY SUPPLEMENT TABLETS CONTAINING THE EXTRACT OF MANGOSTEEN FRUIT RIND. Khoprasert, Methanee; Srichaiyon, Pennapa; Insom, Cholthicha; Sirikul, Wiriyapom; Pothitirat, Werayut; Gritsanapan, Wandee; Chitvanich, Orawan // Thai Journal of Pharmaceutical Sciences;SUP2012, Vol. 36, p132 

    The article focuses on a study conducted to develop tablet formulation containing mangosteen rind extract and examine its antioxidant activity. Mangosteen were brought from Talad Thai in Bangkok, Thailand to be used in the study. The study found the presence of antioxidant activity of mangosteen...

  • Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development. Milligan, P A; Brown, M J; Marchant, B; Martin, S W; van der Graaf, P H; Benson, N; Nucci, G; Nichols, D J; Boyd, R A; Mandema, J W; Krishnaswami, S; Zwillich, S; Gruben, D; Anziano, R J; Stock, T C; Lalonde, R L // Clinical Pharmacology & Therapeutics;Jun2013, Vol. 93 Issue 6, p502 

    The pharmaceutical industry continues to face significant challenges. Very few compounds that enter development reach the marketplace, and the investment required for each success can surpass $1.8 billion. Despite attempts to improve efficiency and increase productivity, total investment...

  • Failure of Two Commercial Indexes and Spectral Parameters to Reflect the Pharmacodynamic Effect of Desflurane on EEG. Sascha Kreuer; Jörgen Bruhn; Richard Ellerkmann; Stephan Ziegeler; Darius Kubulus; Wolfram Wilhelm // Journal of Clinical Monitoring & Computing;Apr2008, Vol. 22 Issue 2, p149 

    Abstract Objective  We compared two PK/PD models, one with and one without a plateau effect. Bispectral (BIS, Aspect Medical Systems, Natick, MA, version XP) and Narcotrend™ (NCT, MonitorTechnik, Bad Bramstedt, Germany, Version 4.0) indices were used as an...

  • Canadian ADR reports up in 2003.  // Reactions Weekly;4/24/2004, Issue 998, p3 

    Focuses on the reports received by Health Canada regarding suspected adverse drug reactions (ADR) in 2003. Percentage of the reports which were classified as serious; Increase in the number of ADR cases reported since 1998; Origin of the reports.

  • Rosiglitazone: The Debate Rolls On.  // Reactions Weekly;6/9/2007, Issue 1155, p5 

    The article announces that GlaxoSmithKline (GSK) has issued a Health Canada-endorsed public communication addressing public concerns about safety of Avandia, generically known as rosiglitazone. GSK recommends patients should not stop Avandia treatment without consulting their healthcare...

  • Network pharmacology. Hopkins, Andrew L. // Nature Biotechnology;Oct2007, Vol. 25 Issue 10, p1110 

    The article focuses on a study conducted to illustrate the relationship between drug action and its target. It reports a phenomenon called the polypharmacology in which a single therapeutic drug can act on multiple targets. It discusses that polypharmacology can influence different aspects of...

  • Determining the First Dose. Harris, Rob // Drug Discovery & Development;Sep2011, Vol. 14 Issue 9, p20 

    The article explores the advantages of using the API-in-capsule strategy for early stage clinical evaluation in for first-time-in-man (FTiM) studies in the U.S. The API-in-capsule approach is a cost-effective and time-saving dosage alternative suggestion for FTiM studies to provide information...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics